Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Keytruda

What is Keytruda (Keytruda®)?

Keytruda, pembrolizumabis a prescription medicine, an innovative breakthrough drug, humanized monoclonal antibody.

Keytruda belongs to the “immunotherapy” drugs that help the immune system attack the tumor. This contrasts, for example, with chemotherapy that directly affects tumor cells.

Keytruda and immunotherapy is therapeutic strategy has revolutionized the treatment of cancer in recent years and is one of the most studied strategies in the world for many types of cancer and different stages of treatments.

What is Keytruda used for?

Keytruda is prescribed by an oncologist and is used to treat various types of cancer, for example:

Advanced melanoma skin cancer when the disease has spread or cannot be removed by surgery.

Advanced non small cell lung cancer, NSCLC, for patients with positive for PDL1 and not received chemotherapy and the tumor express EGFR or ALK gene/mutation.

Other cases can be for patients who received platinum chemotherapy and it is no longer working and the patients tumor express EGFR or ALK gene/mutation.

Other cases can be patients that also received an EGFR or ALK inhibitor medicine and it did not work any more.

Advanced head and neck squamous cells cancer, HNSCC. if the disease has returned or spread and previous platinum chemotherapy  is no longer working.

Hodgkin lymphoma, cHL, in adults and children if the disease has returned and if the patients received 3 or more types of treatment.

Bladder and urinary tract cancer, urothelial carcinoma – for  metastatic disease or patients who can not receive cisplatin, or cases of a disease that progresses during chemotherapy treatment.

Cancer types among adults and children that is shown by a laboratory test to be a microsatellite instability high (MSI-H), or a mismatch repair deficient (dMMR) solid tumor.

Here there are a few points to consider, for example the cancer has spread or cannot be removed by surgery and there are no other satisfactory treatment options, or advanced colorectal cancer although a chemotherapy treatment

Advanced stomach cancer or gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma that tests positive for PDL1  if  chemotherapy did not work and the tumor has an abnormal HER2/neu gene/mutation, and the patient received a HER2/neu-targeted medicine.

What is it important to notice?

Ask your Oncologist how to use Keytruda if you are not sure.

The dosage and duration of Keytruda treatment will be determined by the doctor only.

Read the Patient leaflet guide which is enclosed to each package.

Keytruda side effects- Read more >>

We wish you full health!

All rights reserved to Merck Sharp & Dohme Corp., New-Jersey, USA.

To Read More>>

Read our publications on innovative treatments for cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Cervical Cancer – Positive Results with VB10.16

Overview

Cervical cancer is a malignant tumor that grows in different parts of the cervix.

The vast majority of cervical cancers are linked to an infection by the human papillomavirus (HPV), which is a very common virus that gets transmitted through sexual contact.

Unfortunately, when cervical cancer advances (e.g., metastasis), its management becomes very challenging.

In this article, we will cover the preliminary results of a phase II clinical trial regarding VB10.16 with Tecentriq in the management of advanced cervical cancer. First, let us start by defining the two drugs.

What is VB10.16?

VB10.16 is a DNA vaccine that has three parts.

Each part encodes for a specific protein, including:

  • E6/E7 fusion protein of human papillomavirus (HPV), which is the leading cause of cervical cancer
  • Dimerization entity
  • A protein that binds to antigen-presenting cells (APCs)

The purpose of this vaccine is to stimulate innate antineoplastic immunological responses. The drug gets administered via an intramuscular injection.

The first protein stimulates the immune system to attack cancerous cells that contain HPV. However, antigen-presenting cells might interfere early on in the process, preventing this action from occurring. For this reason, scientists added the third protein that blocks APCs temporarily until E6/E7 get internalized within the cells.

What is Tecentriq ?

Tecentriq, also called Atezolizumab, is an anti-PD-L1 monoclonal antibody that aids in the following conditions:

  • Locally advanced or metastatic urothelial carcinoma
  • Metastatic non-squamous, non-small cell lung cancer (Nsq NSCLC)
  • PD_L1 positive unresectable locally advanced or metastatic triple-negative breast cancer
  • Extensive-stage small cell lung cancer.
  • BRAF V600 mutation-positive unresectable or metastatic melanoma

Today, however, we will discuss its role in treating advanced cervical cancer.

The interim results of a phase II clinical trial

This clinical trial combined VB10.16 with Tecentriq  to treat patients with advanced cases of cervical cancer. One of the inclusion criteria was the positivity of HPV16 in all patients.

The Response Rate (The percentage of patients in whom the cancer has decreased by at least 30% in volume or disappeared after treatment) for this treatment was around 21%, with two complete remissions and 6 partial responses. As for the control rate (The percentage of patients whose disease had stopped growing or decreased in size of tumor by at least 30%) was around 64%.

The Response Rate was 26%, and the Disease Control Rate was 77% in PD-L1-positive patients.

Those with a negative PD-L1 demonstrated a Response Rate of 17% and a Disease Control Rate of 58%.

These preliminary results show that a combination of VB10.16 with Tecentriq can give patients with advanced cervical cancer hope and extend survival.

The complete data of this trial will be available in 2023.

Takeaway message

The positive results of this clinical trial give hope to patients with advanced cervical cancer – a condition that is often thought to be rapidly fatal.

We hope that more trials of this kind get conducted to reach the best possible outcome for patients with advanced cases of cancer.

Talk to us so see if we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

 Read more about Cervical cancer>>

Cervical Cancer - Positive Results with VB10.16
Cervical Cancer – Positive Results with VB10.16

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics